| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | NABRIVA | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(2 years ago) | |
| US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(3 years from now) | |
| US8071643 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(4 years from now) | |
| US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(7 years from now) | |
Xenleta is owned by Nabriva.
Xenleta contains Lefamulin Acetate.
Xenleta has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xenleta are:
- US6753445
Xenleta was authorised for market use on 19 August, 2019.
Xenleta is available in solution;intravenous, tablet;oral dosage forms.
Xenleta can be used as treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms.
Drug patent challenges can be filed against Xenleta from 19 August, 2028.
The generics of Xenleta are possible to be released after 23 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
Dosage: SOLUTION;INTRAVENOUS; TABLET;ORAL
XENLETA family patents
